Minnesota is currently home to 2063 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Minneapolis, Rochester, Saint Paul and Duluth. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
NCT04368559
Recruiting
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/31/2025
Locations: University of Minnesota Physicians, Minneapolis, Minnesota
Conditions: Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Register for Updates
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
NCT01652092
Recruiting
This is a standard of care treatment guideline for allogeneic hematopoetic stem cell transplant (HSCT) in patients with primary immune deficiencies.
Gender:
ALL
Ages:
50 years and below
Trial Updated:
01/31/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: SCID, Omenn's Syndrome, Reticular Dysgenesis, Wiskott-Aldrich Syndrome, Bare Lymphocyte Syndrome, Common Variable Immunodeficiency, Chronic Granulomatous Disease, CD40 Ligand Deficiency, Hyper IgM Syndrome, X-linked Lymphoproliferative Disease, Hemophagocytic Lymphohistiocytosis, Griscelli Syndrome, Chediak-Higashi Syndrome, Langerhan's Cell Histiocytosis
Register for Updates
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
NCT01451502
Recruiting
For the next 5-10 years or possibly longer, a high proportion of the Cord Blood Banks (CBB) inventory worldwide will be composed of unlicensed umbilical cord blood (UCB) units. While Food and Drug Administration (FDA)-licensed units will be prioritized, it will always be possible that an unlicensed unit will have known attributes, making it a better source of cells for the given indication. Because of the wide variety of current and potential indications as a source of cells for hematopoietic re... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/31/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Lymphatic Diseases, Hematopoietic Malignancy
Register for Updates
Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment with 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis
NCT06810050
Recruiting
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn about the safety of CGB-500. The main questions it aims to answer are: Does CGB-500 improve atopic dermatitis by decreasing the area affected and the severity of the lesions? What medical problems do participants have when taking CGB500? Researchers will compare CGB-500 to a placebo (a look-alike substance that contains no drug) to see if CGB-500 w... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
01/30/2025
Locations: J&S Studies, Inc., New Brighton, Minnesota
Conditions: Atopic Dermatitis (AD)
Register for Updates
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
NCT05984199
Recruiting
This is a Phase 1/2, multicenter, open-label, first-in-human (FIH) study of donor-derived anti-CD33 Chimeric Antigen Receptor (CAR) T cell therapy (VCAR33) in patients with relapsed or refractory Acute Myeloid Leukemia (AML) after human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (alloHCT).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Leukemia, Myeloid, Acute
Register for Updates
A Study of Liposomal Bupivacaine Versus 0.25% Bupivacaine Hydrochloride Post Breast Reduction
NCT05891613
Recruiting
The purpose of this research is to assess pain scores and opioid use when using Liposomal (Exparel) Bupivacaine versus Bupivacaine Hydrochloride.
Gender:
FEMALE
Ages:
Between 18 years and 70 years
Trial Updated:
01/30/2025
Locations: Mayo Clinic Minnesota, Rochester, Minnesota
Conditions: Breast Reduction
Register for Updates
Senolytics To slOw Progression of Sepsis (STOP-Sepsis) Trial
NCT05758246
Recruiting
The long-term goal is to test the clinical efficacy of senolytic therapies to reduce progression to and severity of sepsis in older patients. The central hypothesis is that a threshold burden of SnCs predisposes to a SASP mediated dysfunctional response to PAMPs, contributing to a disproportionate burden of sepsis in older patients. The study hypothesizes timely treatment with fisetin will interrupt this pathway. A multicenter, randomized, adaptive allocation clinical trial to identify the most... Read More
Gender:
ALL
Ages:
65 years and above
Trial Updated:
01/30/2025
Locations: Ridges, Burnsville, Minnesota
Conditions: Sepsis, Acute Infection, Organ Failure
Register for Updates
Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)
NCT05238519
Recruiting
The overall goal of this study is to promote awareness of Familial Hypercholesterolemia (FH). The investigators aim to enroll patients with suspected FH into the study and will randomize them to receive usual care or motivational interview. Primary study outcomes include knowledge of FH, as well as clinical and patient-reported outcomes. This study aims to promote optimal disease management and improve outcomes of FH patients.
Gender:
ALL
Ages:
Between 2 years and 75 years
Trial Updated:
01/30/2025
Locations: Aspirus St. Luke's Hospital, Duluth, Minnesota
Conditions: Familial Hypercholesterolemia, Cholesterol, Elevated, Genetic Disease
Register for Updates
Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases
NCT05122962
Recruiting
This study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in heart structure in patients with congenital heart disease (CHD)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Mayo Clinic in Rochester, Rochester, Minnesota
Conditions: Tetralogy of Fallot, Congenital Heart Disease
Register for Updates
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment with Mylotarg, for Patients with CD33+ AML or MDS
NCT04849910
Recruiting
This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
01/30/2025
Locations: Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota
Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Register for Updates
Implications of the Human Microbiota for Health and Disease
NCT04203303
Recruiting
The purpose of this study is to advance the understanding of human health and disease as it relates to environmental factors that may affect intestinal and non-intestinal microbiota.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Mayo Clinic, Rochester, Minnesota
Conditions: Human Microbiota
Register for Updates
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
NCT04174157
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: University of Minnesota, Minneapolis, Minnesota
Conditions: Spinal Muscular Atrophy (SMA)
Register for Updates